Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A; GISMM Cooperative Group; GISL Cooperative Group; GIMEMA Cooperative Group. Musto P, et al. Among authors: guariglia r. Cancer. 2007 Jun 1;109(11):2285-90. doi: 10.1002/cncr.22700. Cancer. 2007. PMID: 17469169 Free article.
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Musto P, Scalzulli PR, Terruzzi E, Rossini F, Iacopino P, Messina G, Guariglia R, Pietrantuono G, Villani O, D'Auria F, Falcone A, Sanpaolo G, Valvano MR, Pogliani EM, Morabito F. Musto P, et al. Among authors: guariglia r. Leuk Res. 2007 Nov;31(11):1487-93. doi: 10.1016/j.leukres.2007.01.008. Epub 2007 Feb 23. Leuk Res. 2007. PMID: 17320951
Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.
Musto P, Villani O, Martorelli MC, Pietrantuono G, Guariglia R, Mansueto G, D'Auria F, Grieco V, Bianchino G, Sparano A, Zonno A, Lerose R, Sanpaolo G, Falcone A. Musto P, et al. Among authors: guariglia r. Leuk Res. 2010 Aug;34(8):981-5. doi: 10.1016/j.leukres.2009.10.022. Epub 2009 Nov 20. Leuk Res. 2010. PMID: 19931907
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N, Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group. D'Arena G, et al. Among authors: guariglia r. Leuk Lymphoma. 2011 May;52(5):771-5. doi: 10.3109/10428194.2011.553000. Epub 2011 Feb 8. Leuk Lymphoma. 2011. PMID: 21299465 Clinical Trial.
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, Musto P. D'Arena G, et al. Among authors: guariglia r. Ann Oncol. 2012 Jun;23(6):1499-502. doi: 10.1093/annonc/mdr480. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039089 Free article.
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.
D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P. D'Arena G, et al. Among authors: guariglia r. Am J Hematol. 2012 Jun;87(6):628-31. doi: 10.1002/ajh.23170. Epub 2012 Mar 28. Am J Hematol. 2012. PMID: 22460620 Free article.
48 results